Assessing Internal Reproducibility Within a Parkinson’s Disease Cohort by Leveraging an Independent Larger Dataset

Background: Parkinson's disease (PD) is a complex and heterogeneous disorder that is likely composed of several phenotypic subgroups with distinct clinical features and patterns of disease progression. Cluster analysis, which categorizes subjects into groups of “maximal similarity”, is a valuable statistical tool for characterizing phenotypic variability in clinical cohorts and for correlating phenotypes with specific biomarkers. However, data collection methods often differ between clinical and research settings, limiting the ability to obtain statistically significant results from smaller or less characterized cohorts and to compare results across studies. Establishing reproducibility of clinical cluster analysis across different studies/centers would allow generalizability across studies. The goal of this study was to leverage cluster analysis of clinical traits to establish reproducibility of clinical phenotypes in a cohort of patients with PD at local centers (Discovery cohort) and the large PD bioregistry Parkinson's Progression Markers Initiative (PPMI cohort). Methods: Nonhierarchical k-means clustering by phenotype of subjects in the Discovery (n = 179) and PPMI (n = 368) cohorts was performed via principal component analysis (cohort-based clusters). Eigenvectors of clustering in the PPMI cohort were identified and utilized to re-cluster the Discovery cohort (PPMI-based clusters). Overlap in cluster membership between cohort-based clusters and PPMI-based clusters of the Discovery cohort was assessed. Results: Clustering of subjects revealed two clusters in the Discovery cohort and three clusters in the PPMI cohort. The first four principal components for clustering of the PPMI cohort, accounting for 43% of the variability, were driven by depression, anxiety, age at symptom onset, gender, and a tremor-dominant phenotype. After re-clustering the Discovery cohort based on these traits, 89% of subjects remained in their original cluster (κ = 0.776, P < 0.01). Conclusions: We successfully leveraged cluster analysis of clinical traits in PD patients from the larger and standardized PPMI cohort to validate reproducibility of clustering in our smaller Discovery cohort. We propose a combination of nonhierarchical cluster analysis and testing of generalizability with re-clustering to establish clustering reproducibility. This method can be adapted for use in a wide range of clinical scenarios, allowing for analysis of cohorts that are less extensively characterized or those with low intrinsic power secondary to low sample size. J Neurol Res. 2024;14(2):49-58 doi: https://doi.org/10.14740/jnr761

Authors

Institutions

Publication Details

Journal
Journal of Neurology Research
Published
2024-11-15
DOI
https://doi.org/10.14740/jnr761
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Assessing Internal Reproducibility Within a Parkinson’s Disease Cohort by Leveraging an Independent Larger Dataset

Charalambos Argyrou, Kristen Watkins, Kelly Astudillo, Julia Greenberg et al.
Journal of Neurology Research
Parkinson's Disease Mechanisms and Treatments
article

Assessing Internal Reproducibility Within a Parkinson’s Disease Cohort by Leveraging an Independent Larger Dataset

Charalambos Argyrou, Kristen Watkins, Kelly Astudillo, Julia Greenberg, Wen-Yu Lee, Towfique Raj, Giulietta Riboldi, John F. Crary, Steven J. Frucht
article en

Abstract

Background: Parkinson's disease (PD) is a complex and heterogeneous disorder that is likely composed of several phenotypic subgroups with distinct clinical features and patterns of disease progression. Cluster analysis, which categorizes subjects into groups of “maximal similarity”, is a valuable statistical tool for characterizing phenotypic variability in clinical cohorts and for correlating phenotypes with specific biomarkers. However, data collection methods often differ between clinical and research settings, limiting the ability to obtain statistically significant results from smaller or less characterized cohorts and to compare results across studies. Establishing reproducibility of clinical cluster analysis across different studies/centers would allow generalizability across studies. The goal of this study was to leverage cluster analysis of clinical traits to establish reproducibility of clinical phenotypes in a cohort of patients with PD at local centers (Discovery cohort) and the large PD bioregistry Parkinson's Progression Markers Initiative (PPMI cohort). Methods: Nonhierarchical k-means clustering by phenotype of subjects in the Discovery (n = 179) and PPMI (n = 368) cohorts was performed via principal component analysis (cohort-based clusters). Eigenvectors of clustering in the PPMI cohort were identified and utilized to re-cluster the Discovery cohort (PPMI-based clusters). Overlap in cluster membership between cohort-based clusters and PPMI-based clusters of the Discovery cohort was assessed. Results: Clustering of subjects revealed two clusters in the Discovery cohort and three clusters in the PPMI cohort. The first four principal components for clustering of the PPMI cohort, accounting for 43% of the variability, were driven by depression, anxiety, age at symptom onset, gender, and a tremor-dominant phenotype. After re-clustering the Discovery cohort based on these traits, 89% of subjects remained in their original cluster (κ = 0.776, P < 0.01). Conclusions: We successfully leveraged cluster analysis of clinical traits in PD patients from the larger and standardized PPMI cohort to validate reproducibility of clustering in our smaller Discovery cohort. We propose a combination of nonhierarchical cluster analysis and testing of generalizability with re-clustering to establish clustering reproducibility. This method can be adapted for use in a wide range of clinical scenarios, allowing for analysis of cohorts that are less extensively characterized or those with low intrinsic power secondary to low sample size. J Neurol Res. 2024;14(2):49-58 doi: https://doi.org/10.14740/jnr761

Journal of Neurology ResearchVol. 14(2)
Allen Institute for Brain Science (US), NYU Langone Health (US), Icahn School of Medicine at Mount Sinai (US)
U.S. Department of Defense, Bristol-Myers Squibb, Pfizer, Sanofi, Biogen, Teva Pharmaceutical Industries, Celgene, Cincinnati Children's Hospital Medical Center, Union Chimique Belge, Verily Life Sciences, Voyager Therapeutics, Servier, H. Lundbeck A/S, National Institutes of Health, Genentech, Allergan, Sanofi Genzyme
Openalex Percentile: Top 68%
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.